Lexicon Pharmaceuticals: Pay

Lexicon Pharmaceuticals paid CEO Michael S. Exton, Ph.D. $3.6M in FY2025 (Dec). No other named executive of that year is on file.

Pay$100 in the stock at the end of FY23 → $75
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Michael S. Exton, Ph.D.Chief Executive Officer and Director
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2023 (Dec), the median CEO pay of the 2 peers with pay on file was $20.1M. The CEO of Lexicon Pharmaceuticals was paid $4.1M, 80% below the median.

  1. 1Madrigal Pharmaceuticals
  2. 2Enanta Pharmaceuticals
  3. 3Lexicon Pharmaceuticals
  4. 42seventy bio, Inc.Not disclosed
  5. 5Amarin Corporation plcNot disclosed
  6. 6Arcutis BiotherapeuticsNot disclosed
  7. 7Catalyst Pharmaceuticals, Inc.Not disclosed
  8. 8Chinook Therapeutics, Inc.Not disclosed
  9. 9Esperion Therapeutics, Inc.Not disclosed
  10. 10G1 Therapeutics, Inc.Not disclosed
  11. 11GeronNot disclosed
  12. 12Inovio Pharmaceuticals, Inc.Not disclosed
  13. 13Karyopharm Therapeutics, Inc.Not disclosed
  14. 14Reata Pharmaceuticals, Inc.Not disclosed
  15. 15Y-mAbs Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.